MON-546 Euglycemic Diabetic Ketoacidosis With Recent Initiation Of A SGLT2 Inhibitor Medication In A Patient With T2D
Abstract
Abstract Disclosure: N. Bhuiya: None. F. Ziyadeh: None. P. Rao: None. Euglycemic diabetic ketoacidosis (EDKA) is a clinical syndrome comprised of euglycemia, ketonemia, and severe metabolic acidosis among individuals with type 1 or type 2 diabetes. With the rise of usage of sodium-glucose transporter 2 (SGLT2) inhibitors, the incidence of EDKA has increased. Without hyperglycemia at presentation, a hallmark sign of DKA, the diagnosis of EDKA can be delayed. We report a case of a 43-year-old female with a history of uncontrolled type 2 diabetes (T2D), hypertension, high-grade squamous intraepithelial lesion of the cervix status-post LEEP, and glaucoma who presented with palpitations, pleuritic chest pain, nausea, lower abdominal pain, back pain, chills and weakness for approximately 2-3 days. Of note, the patient had started empagliflozin 10mg 3 days prior to presenting to the hospital. The patient was previously on dulaglutide and metformin, however, she was only prescribed empagliflozin for current diabetes management. Laboratory tests revealed glucose 166 mg/dL, pH 7.20 on VBG, bicarbonate 9 mmol/L, anion gap 37 mmol/L, and beta-hydroxybutyrate 6.86 mmol/L, which were concerning for euglycemic DKA. Additional laboratory tests exhibited normal C-peptide levels and negative insulin antibody and glutamic acid decarboxylase (GAD). Treatment with IV insulin and IV fluids led to clinical improvement. The patient was discharged with Lantus 20 units and sliding scale insulin…
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.